1. Home
  2. DGII vs PHVS Comparison

DGII vs PHVS Comparison

Compare DGII & PHVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Digi International Inc.

DGII

Digi International Inc.

N/A

Current Price

$69.44

Market Cap

2.6B

Sector

Technology

ML Signal

N/A

Logo Pharvaris N.V.

PHVS

Pharvaris N.V.

N/A

Current Price

$36.03

Market Cap

2.4B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
DGII
PHVS
Founded
1985
2015
Country
United States
Switzerland
Employees
N/A
N/A
Industry
Computer peripheral equipment
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.6B
2.4B
IPO Year
1995
2020

Fundamental Metrics

Financial Performance
Metric
DGII
PHVS
Price
$69.44
$36.03
Analyst Decision
Strong Buy
Buy
Analyst Count
5
11
Target Price
$48.80
$41.82
AVG Volume (30 Days)
353.2K
617.5K
Earning Date
05-06-2026
05-12-2026
Dividend Yield
N/A
N/A
EPS Growth
77.05
N/A
EPS
1.00
N/A
Revenue
$430,221,000.00
N/A
Revenue This Year
$18.71
N/A
Revenue Next Year
$7.22
N/A
P/E Ratio
$69.31
N/A
Revenue Growth
1.46
N/A
52 Week Low
$33.74
$20.65
52 Week High
$86.84
$38.13

Technical Indicators

Market Signals
Indicator
DGII
PHVS
Relative Strength Index (RSI) 37.96 52.36
Support Level $64.12 $24.55
Resistance Level $70.30 $36.36
Average True Range (ATR) 2.83 1.45
MACD -1.39 -0.18
Stochastic Oscillator 10.02 43.19

Price Performance

Historical Comparison
DGII
PHVS

About DGII Digi International Inc.

Digi International Inc is a Minnesota corporation that provides business and mission-critical Internet of Things (IoT) connectivity products and services. It operates through two segments: IoT Products & Services, which supports OEMs, enterprise, and government customers in deploying secure IoT connectivity solutions, and IoT Solutions, consisting of SmartSense and its Managed Network-as-a-Service (MNaaS) business offering wireless temperature and condition-based monitoring, employee task management, label printing, and other services. The company generates the majority of its revenue from the IoT Products & Services segment and mainly from the United States, with a presence in Europe, the Middle East and Africa, and the Rest of the world.

About PHVS Pharvaris N.V.

Pharvaris NV is a late-stage biopharmaceutical company which is engaged in developing novel, oral bradykinin B2 receptor antagonists to prevent and treat HAE attacks. By directly pursuing this clinically therapeutic target with novel small molecules, With positive data in both Phase 2 prophylaxis and studies in HAE, Pharvaris is developing deucrictibant. Pharvaris is currently enrolling a pivotal Phase 3 study for the treatment of HAE attacks and plans to initiate a pivotal Phase 3 study of deucrictibant for the prevention of HAE attacks. The company is also running open-label extension studies in both on-demand (RAPIDe-2) and prophylactic (CHAPTER-4) settings to collect long-term safety and efficacy data in HAE patients.

Share on Social Networks: